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Signposts for repurposing from sixty years of metformin use 
Although introduced for use as a diabetic medication in 1957, metformin remains the 
cornerstone of diabetic drug management in patients with type 2 diabetes mellitus (T2D). 
Its widespread use has largely been underpinned by the United Kingdom Prospective 
Diabetes Study (UKPDS) that reported lower cardiovascular mortality and morbidity in 
patients treated with metformin compared with alternative glucose-lowering drugs, 
despite similar glycemic control. Recent meta-analysis suggests that the cardiovascular 
effects of metformin could be smaller than that reported by UKPDS; however, this should 
be interpreted with caution as there has only been a small number of randomized 
controlled trials (1).  While CVD patients with T2D comorbidity are likely to benefit most 
from metformin, indications of CV benefit over other diabetes treatments has driven 
interest in repurposing metformin to treat CVD, irrespective of diabetes status.  
Identified before the era of target-driven drug discovery programs, metformin’s cellular 
mechanism is poorly established. The most likely cellular effect underlying 
antihyperglycemic responses is inhibition of mitochondrial enzymes, including complex I. 
Mitochondrial suppression by metformin activates AMP-activated protein kinase (AMPK); 
however, AMPK-independent targets also contribute to effects on glycemia and in 
addition, benefits of the drug in CVD may also be exerted by mechanisms distinct from 
its metabolic actions. In our recent work for example, we have been studying anti-
inflammatory effects of the drug through suppression of the NF-κB inflammatory signalling 
pathway (2). We traced these effects back to mitochondrial inhibition, consistent with 
other evidence of mitochondrial regulation of inflammation (3). Following up these studies 
in a large, treatment-naive diabetes mellitus population cohort, we confirmed this effect 
in humans by observing that compared with sulfonylureas (another T2D drug), metformin 
suppressed the systemic inflammation marker, neutrophil to lymphocyte ratio (NLR), 
which is a known predictor of all-cause mortality and cardiovascular events. We also 
found that metformin suppressed plasma cytokines in patients without diabetes who had 
heart failure, including the aging-associated cytokine CCL11 (C-C motif chemokine ligand 
11). Blockade of CCL11 can suppress aspects of age-related cellular dysfunction and 
further investigation is required to determine whether observed effects of metformin on 
mammalian longevity, where suppression of NF-κB is also observed, owe at least in part 
to cardioprotective benefits arising from suppression of this and other cytokines.  
Immunometabolism as a drug target for metformin in CVD? 
Inflammation is understood to contribute to CVD but existing non-steroidal anti-
inflammatory drugs (NSAIDs) and anti-TNF drugs have shown limited utility in CVD 
treatment. There is still a strong belief however that anti-inflammatory strategies are worth 
pursuing, key exemplars of which are the recent CIRT (NCT01594333) and CANTOS 
(NCT01327846) trials. If inflammation is to be targeted successfully in CVD it is likely that 
other agents, with different anti-inflammatory mechanisms will need to be studied. Control 
of immunity through changes in metabolism-‘immunometabolism’ (4), such as is exhibited 
by metformin, is becoming recognized as an additional potential site of therapy even in 
non-diabetic age-related disease.  
RCTs in patients without T2D 
Despite encouraging data in T2D, recent findings on CVD benefit from prospective 
studies in groups without T2D have so far been mixed. In subjects without diabetes who 
have cardiac syndrome X with normal coronary arteriography but two consecutive positive 
exercise tolerance tests, an 8-week period of metformin treatment improved maximal ST-
segment depression, Duke score and chest pain incidence compared with placebo (5) 
(Table 1). The ‘proof of concept’ TAYSIDE trial in patients without diabetes who have 
heart failure and insulin resistance found a beneficial effect of metformin on its secondary 
outcome of VE/VCO2 slope, a prognostic measure of exercise capacity (NCT00473876). 
However, the CAMERA trial (NCT00723307) on patients with insulin resistance but 
without diabetes who had coronary artery disease already taking statins showed no effect 
of metformin on carotid artery intima-media thickness (CIMT).  In addition, the GIPS-III 
trial (NCT01217307) on metformin in ST-segment elevation myocardial infarction 
(STEMI) patients without diabetes showed little or no effect of metformin. In contrast, the 
recent REMOVAL trial (NCT01483560) in type 1 diabetes did show an effect on the pre-
specified tertiary endpoint of maximal carotid-artery intima-media thickness, despite no 
sustained effect on glycemia, possibly consistent with a CV effect of the drug that is not 
due to changes in glycemia. Further studies with metformin are ongoing (Table 1). Recent 
evidence from the EMPA-REG OUTCOME trial (NCT01131676) showed that the SGLT2 
inhibitor, empagliflozin, another T2D drug, lowered CVD mortality in T2D patients with 
prevalent ASCVD. This may largely be independent of effects on glycemia, similar to the 




The present clinical equipoise for metformin in CVD without T2D has led to a call for CV 
endpoint trials of metformin in the absence of diabetes (1) and it is timely to consider how 
future repurposing RCTs might be designed. Since pharmaceutical companies are 
unlikely to fund large-scale trials of metformin, public funding agencies should give 
consideration to supporting these. New diabetes-independent plasma markers of drug 
response might find utility as surrogate endpoints in trials, such as inflammatory 
biomarkers. Such biomarkers might be especially useful in short-term trials where ‘hard’ 
endpoints, such as mortality, are delayed. Arguably, an even more critical role for such 
inflammatory biomarkers may ultimately prove to be better stratification of patient groups, 
before their entry into trials. A compelling exemplar of the power of this approach is the 
recently completed CANTOS trial (NCT01327846) of an IL-1β antibody, which selected 
for trial only those individuals with persistently high inflammatory burden. Where others 
have not succeeded in the past, this study has established inflammation as a viable target 
in CVD.  
Concluding remarks 
In conclusion, a variety of evidence suggests that metformin has potential as a treatment 
for CVD irrespective of diabetes status but prospective randomized trials to repurpose the 
drug in individuals without diabetes have so far been largely neutral on CV-related 
outcomes. Future RCTs, incorporating better stratification/targeting, using novel 
preclinical markers of diabetes-independent inflammation might establish the utility of 
metformin and therefore help to prioritize metformin repurposing over other emerging 
CVD treatments.  
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